FDA Clears Path for Neurizon’s NUZ-001 in ALS Trials
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Neurizon Therapeutics Limited’s lead investigational therapy, NUZ-001, which is aimed at treating Amyotrophic Lateral Sclerosis (ALS). This…